original ) (raw )PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease
Lars Farde
Brain, 1997
View PDFchevron_right
Extrastriatal dopamine D2 receptor binding in Huntington's disease
Joakim Tedroff
Human Brain Mapping, 2010
View PDFchevron_right
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study
Nicola Pavese
Brain, 2003
View PDFchevron_right
Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington’s disease
Antoon Willemsen
European Journal of Neurology, 2009
View PDFchevron_right
Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia
Jeffrey Joyce
Synapse, 1988
View PDFchevron_right
Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex
Ladislav Mrzljak
Journal of Nuclear Medicine, 2016
View PDFchevron_right
Extrastriatal dopamine D 2 receptor binding in Huntington's disease
Andrea Varrone
Human Brain Mapping, 2011
View PDFchevron_right
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study
michal geva
European Journal of Nuclear Medicine and Molecular Imaging, 2020
View PDFchevron_right
Longitudinal microPET imaging of the zQ175 mouse model of Huntington's disease shows in vivo changes of molecular targets in the striatum and the cerebral cortex
Jonathan Bard
Journal of Nuclear Medicine, 2016
View PDFchevron_right
Dopamine and Huntington’s disease
Sarah Mason
Expert Review of Neurotherapeutics, 2015
View PDFchevron_right
Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease
Rlm Faull
Annals of Neurology, 1997
View PDFchevron_right
Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease
jm. vignesh
Journal of …, 2006
View PDFchevron_right
Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease
Faye Begeti
2014
View PDFchevron_right
Impaired dopamine release and uptake in R6/1 Huntington's disease model mice
Andrea Ortiz
Neuroscience Letters, 2011
View PDFchevron_right
Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11 C-N-methyl-spiperone
Bengt Långström
Acta Neurologica Scandinavica, 1987
View PDFchevron_right
Clinical deficits in Huntington disease correlate with reduced striatal uptake on iodine-123 epidepride single-photon emission tomography
Douglas Hobson
European Journal of Nuclear Medicine and Molecular Imaging, 1999
View PDFchevron_right
Does reduced [ 123I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement
Carles Lorenzo-Bosquet
Clinical Neurology and Neurosurgery, 2010
View PDFchevron_right
Striatal neurochemical changes in transgenic models of Huntington's disease
Danilo Tagle
Journal of Neuroscience Research, 2002
View PDFchevron_right
[11C]Raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length
K. Leenders , Angelo Antonini
Annals of Neurology, 1998
View PDFchevron_right
Iodine-123-IBZM Dopamine D2 Receptor and Technetium-99m-HMPAO Brain Perfusion SPECT in the Evaluation of Patients with and Subjects at Risk for Huntington's Disease
Luis Fornazzari
Journal of Nuclear Medicine
View PDFchevron_right
Hypothalamic involvement in Huntington's disease: an in vivo PET study
Marios Politis
Brain, 2008
View PDFchevron_right
Striatal glucose metabolism and dopamine D 2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
Roland Spiegel
Brain, 1996
View PDFchevron_right
Dopamine Modulates the Susceptibility of Striatal Neurons to 3-Nitropropionic Acid in the Rat Model of Huntington’s Disease
David Reynolds
The Journal of Neuroscience, 1998
View PDFchevron_right
The role of dopamine in huntington's disease
Carlos Cepeda
Progress in Brain Research, 2014
View PDFchevron_right
Dopamine and Glutamate in Huntington’s Disease
Carlos Cepeda
Dopamine and Glutamate in Psychiatric Disorders, 2005
View PDFchevron_right
Benzodiazepine receptor quantification in Huntington's disease with [123I]iomazenil and SPECT
Sven Sørensen
Journal of Neurology, Neurosurgery & Psychiatry, 2001
View PDFchevron_right
Motor function and dopamine release measurements in transgenic Huntington's disease model rats
Michael Johnson
Brain Research, 2012
View PDFchevron_right
Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation
Stephan von Hörsten , Carsten Holzmann
Journal of Neurochemistry, 2005
View PDFchevron_right
Resolving pathobiological mechanisms relating to Huntington disease: gait, balance, and involuntary movements in mice with targeted ablation of striatal D1 dopamine receptor cells
Ilse Gantois
Neurobiology of disease, 2014
View PDFchevron_right